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 The enormous prevalence of infections caused by parasitic nematodes worldwide, coupled to the 
rapid emergence of their resistance to commonly used anthelmintic drugs, presents an urgent need 
for the discovery of new drugs. Herein, we have identified several classes of small molecules with 
broad spectrum activity against these pathogens. Previously, we reported the identification of 
carnitine palmitoyltransferases (CPTs) as a representative class of enzymes as potential targets for 
metabolic chokepoint intervention that was elucidated from a combination of chemogenomic 
screening and experimental testing in nematodes. Expanding on these previous findings, we have 
discovered that several chemical classes of known small molecule inhibitors of mammalian CPTs 
have potent activity as anthelmintics. Cross-clade efficacy against a broad spectrum of adult parasitic 
nematodes was demonstrated for multiple compounds from different series. Several analogs of these 
initial hit compounds were designed and synthesized. The compounds we report represent a good 
starting point for further lead identification and optimization for development of new anthelmintic drugs 
with broad spectrum activity and a novel mechanism of action. 
 
Keywords: Parasitic nematodes; hookworm, whipworm, filarial nematode, whole worm assay, in 
vitro, in vivo, target class repurposing, Carnitine palmitoyltransferase (CPT), bioaccumulation, 
anthelmintic.  
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Parasitic nematodes (roundworms) are the causative agents responsible for multiple infectious 
diseases affecting over 2 billion people1, as well as contributing to loss of 10% of cultivated crops2 
and substantially reducing production of meat, milk and wool in domestic livestock3 worldwide. 
Although not commonly fatal in humans, these diseases significantly contribute to an enormous 
economic burden associated with lost productivity and perpetuation of poverty cycle (>3 million years 
lived with disabilities (YLDs)) as well as imposing a heavy burden on associated healthcare costs. 
Indeed, they are among the most prevalent of parasitic diseases worldwide. The combination of the 
global healthcare burden, their prevalence, and lack of effective treatment options have led to their 
inclusion in the World Health Organization’s (WHO) list of neglected tropical diseases.4 
Mass drug administration (MDA) programs over the last two decades have led to a significantly 
reduced prevalence of some, but not all, of these diseases. Unfortunately, these efforts use only a 
small number of antiparasitic drug classes5, mostly benzimidazoles (e.g. albendazole), targeting 
tubulin in nematodes (intestinal infections) and macrocyclic lactones (e.g. ivermectin) targeting 
chloride ion channels, and used in combination with diethylcarbamazine (an inhibitor of arachidonic 
acid metabolism) for filarial MDAs6-7. Importantly, the large scale usage of these drugs has led to 
wide-spread resistance in parasitic nematodes of farm animals and concerns of similar resistance 
either crossing over or independently emerging in human parasites, which may already be occurring.8 
In recent years, a limited number of new drugs with diverse mechanisms of action have been 
championed. These include the nicotinic receptor agonists (tribendimidine) or antagonists 
(monepantel)9 as well as a drug that has been proposed to target the protein kinase C signaling 
cascade (emodepside)10. However, none of these newly identified drugs are yet approved for use in 
humans, and resistance may quickly evolve against them, as shown for monepantel against the 
barber’s pole worm Haemonchus contortus.11 Therefore, there is a pressing need to develop novel 
small molecule anthelmintics encompassing new modes of actions.  
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 One strategic opportunity to identify an entirely novel class of anthelmintic(s) is to target 
metabolic pathways essential to the viability of the parasites12-13. Given the accelerated pace and 
increased availability of genome scale information related to parasitic nematodes, it is possible to 
perform pan-phylum comparative analyses of genes and pathways involved, for example, with 
metabolism.13 These pan-phylum analyses have the potential to identify novel targets of essential 
metabolism and to guide the development of drugs with new modes of action with broad applicability 
across the diverse clades of the phylum Nematoda. This is desirable since co-infections with multiple 
parasitic species routinely occur, and economics disfavor the development of drugs for individual 
parasites. Previously, knowledge-based targeting of metabolic networks for pathogens has been used 
to identify novel candidates for drugs.14 Specifically, enzymes that either uniquely consume or 
produce a metabolite (termed “chokepoint” enzymes)  have been targeted; inhibition of chokepoint 
activity is expected to be deleterious due to the absence of alternative pathways to compensate for 
their function. Similar approach at a much smaller scale has been applied to nematodes by this 
group12 where putative chokepoints in multiple species of worms were identified and a prioritization of 
both the individual chokepoint enzymes and their associated inhibitors in drug-target databases was 
performed. 
The carnitine palmitoyltransferase (CPT) family of enzymes (EC 2.3.1.21) is a chokepoint in 
nematodes. CPTs are mitochondrial membrane-embedded enzymes that participate in transport of 
long chain fatty acids from the cytoplasm to the internal matrix of the mitochondrion, where they can 
be oxidized to release energy. Several classes of small molecule inhibitors have been described as 
CPTs were promising targets for type 2 diabetes and insulin resistance for many years15-16. Available 
chemical classes of inhibitors include oxirane carboxylic acids, which are irreversible covalent 
inhibitors and acylcarnitine analogs which are substrate competitive inhibitors.15 Further, homologous 
enzymes in humans have been reported to be targeted by perhexiline (PHX),15 a marketed drug 
indicated for treatment of angina pectoris and ischemic heart disease.17 In our previous work,  we 
showed PHX to be effective against the early larval stages of Caenorhabditis elegans, the blood-
Page 5 of 50
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 feeding parasitic nematode H. contortus, and the filarial nematode Onchocerca lienalis.12 However, 
efficacy against adult parasites, which are the targets of chemotherapy, had not yet been shown. 
To expand on our initial findings, we undertook a target class repurposing18 approach and 
tested known drug-like small molecule CPT inhibitors of the mammalian enzymes CPT1A, 1B and 
CPT2. To this end, we first purchased several compounds known to be CPT inhibitors and then 
synthesized representative examples of three other classes of heterocyclic CPT inhibitors that were 
not commercially available. Next, we developed a homology model of the nematode enzyme CPT2 
and rationally designed analogs with modifications to selectively target nematode CPT2 over 
mammalian CPT2. We have systematically studied gene sequence variations (e.g., indels) among 
nematodes and hosts, where we identified variants specific to the phylum Nematoda. We 
subsequently characterized their structural impact on the variant proteins and then proposed their 
relevance to selective anthelmintic drug targeting.19 These compounds were synthesized and tested 
in vitro for their efficacy using phenotypic whole worm assays with a broad variety of nematode 
species having diverse modes of parasitism, including hookworms and whipworms, which reside 
within the lumen of the intestine, as well as filariids which live within the blood and solid tissues. PHX 
was further tested in an in vivo assay using hamsters infected with the intestinal zoonotic hookworm 
parasite, Ancylostoma ceylanicum.  
 
RESULTS AND DISCUSSION  
Hit identification of initial compounds for targeting nematodes 
Two orthogonal approaches, both based on an underlying target class repurposing strategy, 
were followed to identify potential anthelmintics, based on existing mammalian CPT inhibitors. First, 
chemogenomic screening was performed to locate CPT homologs (Table S1) among the target 
proteins in the ChEMBL database using sequence similarity. This process identified 105 candidate 
compounds (Table S2), including PHX (P1 in Figure 1A) which has been reported to be active against 
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 the free living nematode C. elegans as well as larval stages of intestinal and filarial nematode 
parasites.12 P1 is a clinically used antianginal agent that weakly inhibits both CPT1 and CPT2 in 
humans,15 as well as other targets including certain Ca2+ and K+ channels.20 A subset of these 105 
compounds was selected by structural diversity, employing a stepwise scheme of prioritization. First, 
the compounds were clustered based on their fingerprint Tanimoto similarity scores21 and 
subsequently, compounds were rejected based on undesired physical properties22, lack of 
commercial availability, and cost.23 This filtering strategy resulted in the identification of nine 
compounds for testing in a whole organism phenotypic screen, of which five (P1-P5) were initially 
selected for screening (Figure 1A and Table S3).  
 In a parallel second approach, four known small molecule inhibitors of mammalian CPT1A, 1B 
and CPT215 were synthesized (Schemes 1 and 2). These are compounds 6a, 10a, 17a, and 17b. 6a 
and 10a belong to the phenoxyacetamide piperidinyl, and bis-phenylsulfonamide acid series of 
inhibitors, respectively. 17a and 17b (Scheme 2) are conformationally restricted analogs of the latter 
series which cyclize the sulfonamide into a fused ring. 6a is known to target rat and human CPT1A 
potently and selectively over CPT1B with some activity for CPT2. In contrast, 10a is less active for 
CPT1A and shows some activity for CPT1B and CPT2. 17a is 10-fold more potent inhibitor of CPT1A 
relative to 10a and is totally selective over CPT1B, like 6a. 17b is similar to 10a since it has less 
CPT1A potency and is the most active against CPT1B. Of all compounds, 17a is the most active 
against CPT2. These compounds were chosen for synthesis and biological evaluation because they 
belong to four different chemical series in addition to their different selectivity profiles for the CPT 
isoforms. 
 
Compound screening with parasitic nematodes in a phenotypic motility assay 
The resulting nine compounds that we identified and prioritized were experimentally screened 
with five diverse species of parasitic nematodes that broadly span the phylum Nematoda by including 
representatives from three nematode clades24 (Figure 2): Clade I (whipworm Trichuris muris), Clade 
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 III (filarial Brugia pahangi) and clade V (strongylids Ancylostoma ceylanicum, Nippostrongylus 
brasiliensis and Heligmosomoides polygyrus). For these tests, the adult developmental life cycle 
stages of each species were assayed. The adult stage of the worm generally represents the most 
relevant form for assessing their susceptibility to anthelmintic therapy and can display different 
responses from those of worms at the larval stages.  This is particularly relevant for compounds that 
target metabolism, which can vary substantially during the developmental cycle of the nematode13. 
For example, larval stages of some soil transmitted helminths (STHs), such as hookworms, live in the 
soil, whereas the adult forms parasitize the GI tract of the mammalian host. These assays also 
included known anthelmintics as positive controls (pyrantel for hookworm and levamisole for 
whipworm) and a negative control (DMSO).  
Three of the five compounds from the first set of candidate inhibitors (P1, P2, P5) showed 
deleterious effects on one or more parasitic species (Figure 2). It was gratifying to find that P1 (PHX) 
showed good potency against the worms but it is very structurally distinct from other known CPT 
modulators15. Whereas it has long been thought that antianginal activity of PHX may be a direct 
consequence of its inhibition of CPT2 (or other unknown) activity, resulting in the fuel switch from fatty 
acid to glucose in the heart, PHX may cause more complex metabolic changes.25 P2 showed 
selective activity against T. muris (whipworms)15, 26-27 while P5 showed broad anthelmintic activity 
against both A. ceylanicum (hookworms) and whipworms.15  Of the synthesized analogs, 6a and 10a 
showed significant pan-nematode effects by decreasing the motility of the worms in more than one 
species. Finally, compound 17a showed some activity against hookworms and the filarial species 
B. pahangi. 
In summary, we found that six of the nine compounds tested were deleterious for one or more 
of the parasitic species (Table S4), and three of the six (P1, 6a, 10a) displayed pan-nematode effects 
(inhibiting at least one intestinal and a filarial species). P1 and 6a displayed the best pan-nematode 
effects in the whole worm assay by inhibiting multiple intestinal and filarial species and 10a was 
efficacious in only one intestinal species and a filarial species (Figure 2 and Table S4). 
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Expanding the list of small molecules with pan-phylum inhibition potential  
To expand on the structure activity relationships (SAR) of our hit compounds with the best pan-
phylum inhibitory effect, we searched for available analogs. PHX is used in the clinic only in Australia, 
and New Zealand, but not elsewhere because of hepatic toxicity and peripheral neuropathy in 
patients with impaired metabolism resulting from polymorphism in the cytochrome P-450 enzyme 
(CYP2D6) which leads to high plasma concentrations of the drug.20 Recent findings revealed 
improved pharmacokinetic (PK) properties of synthetic fluorinated analogs of PHX.28 Thus, we 
acquired two of the PHX analogs (cycloalkyl analog P1a and fluorinated analog P1b)28 and 
experimentally screened them against a whipworm and a filariid nematode (Table S3 and Table S4). 
P1a significantly reduced activity in both the whipworm (60 µM at 24 and 48 hrs) and filarial worm 
(inhibition of worm motility of 99% with 75 µM and 175 µM within the first 24 hrs, day 0). Compound 
P1b completely inhibited the whipworm’s motility after 48 hrs with 60 µM and was similar to P1a in 
inhibiting filarial worm motility. While these analogs have improved pharmacokinetic properties, there 
was no effect on their anthelmintic activity relative to PHX. 
In order to further understand our results from the phenotypic screening of the worms, we used 
compounds 6a and 10a to derive initial SAR (Figure 1B) through molecular modeling studies. As 
illustrated in Figure 3, we built a series of CPT2 homology models using an inhibitor-bound Rattus 
norvegicus (rat) X-ray crystal structure (PDB code: 2FW3), for four nematode species (T. muris, 
A. ceylanicum, C. elegans, Strongyloides stercoralis) and three mammalian hosts (Mus musculus, 
Mesocricetus auratus, Homo sapiens). Thereafter, we performed molecular docking studies using 6a, 
10a, 17a, and P1 (Figure 3B). We employed multiple parasitic nematode species for this analysis 
because CPT2 is conserved among nematodes, all orthologs of which are divergent from the 
mammalian ortholog (Table S5).  
Based on this analysis derived from SAR and the molecular modeling studies, we rationally 
designed focused libraries based on 6a and 10a (Figure 4). Two modifications to 6a having the most 
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 productive effect were derivatives of the phenyl ether portion (Scheme 1A). Two additional analogs, 
6n and 6o were designed based on the overlay of 6a with 10a and 17a (Figure 3B), both of which 
contain a phenyl carboxylic acid that makes an electrostatic interaction with the conserved histidine 
residue in human (His372), His571 in hookworm and His380 in whipworm. This was absent in 6a and 
was predicted to improve the binding affinity to CPT2 and improve potency in the motility assay. The 
methyl ester intermediates 6l and 6m were also tested for their activity. It was predicted that the 
methyl esters would increase permeability to the worms, acting as prodrugs and would hydrolyze into 
the predicted active carboxylic acid prior to engaging CPT1 or 2 in the mitochondrial membrane of the 
nematode cell. For 10a, we pursued changing the sulfonamide to a urea with three analogs 24a-c 
(Scheme 3) and also tested the methyl ester derivatives 23a-c as prodrugs of the carboxylic acid 
once again to assess differential effects in penetration of the nematode cuticle. 
  
Synthesis of compounds 
The synthesis of the small molecule inhibitors 6(a-k) are outlined in Scheme 1A (Figure S1-
S15). Reaction of compound 1 acid with ammonium chloride in presence of base yielding amide 2, 
which is converted to thioamide 3 by treating with Lawesson’s reagent. The heterocyclic thiazole 
compound 4 were prepared by refluxing of compound 3 with appropriate 2-bromo (5-substituted 
pyridine)-1-one and CaCO3, which upon Boc-deprotection of intermediate 4 followed by coupling of 
appropriate acid yields 6(a-k). Compounds 10(a-c) were synthesized according to Scheme 1B 
(Figure S16-S18), where reaction of commercially available methyl-3-amino benzoate 8 with an 
appropriate 3,4–substituted benzene sulfonyl chloride 7(a-c) in the presence of base, followed by 
ester hydrolysis yielded compounds 9(a-c). In turn, these intermediates were coupled with methyl-4-
amino benzoate using standard amide bond coupling reagents EDCI/DIPEA/DMF. Subsequent 
hydrolysis of compounds 9(a-c) yielded the final target compounds 10(a-c). 
 The synthesis of inhibitors 17(a-b) is outlined in Scheme 2 (Figure S19-S20).  Condensation of 
compounds 11(a-b) with aryl sulfonyl chlorides 12(a-b) in presence of base (pyridine) yields 
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 sulfonamide intermediates 13(a-b). The methyl esters were converted to the carboxylic acids 14(a-b) 
by basic hydrolysis, followed by coupling with amines 15 (a-b) using EDC/DIPEA/DMF.  The resulting 
amides 16(a-b) were hydrolyzed to provide the final targets 17(a-b). Compounds 24(a-c) are 
functionally distinct analogs of compounds 10(a-c) in which the sulfonamide group is replaced by a 
urea. These were synthesized (Scheme 3; Figure S21-S26) by coupling of amine 18 with 3-nitro 
benzoyl chloride 19 which furnished intermediate 20. Next, sequential catalytic reduction of both 
protecting groups yielded aniline 21. Installation of the urea group was accomplished via reaction with 
isocyanates 22(a-c) giving intermediate esters 23(a-c), which were hydrolyzed to give the carboxylic 
acids 24(a-c). 
 
Biological evaluation of rationally designed nematode inhibitors 
We tested the new analogs for broad spectrum potential by screening three species spanning 
the phylum (Table S5): two intestinal parasites (Clade V – A. ceylanicum and Clade I – T. muris) and 
a filarial parasite (Clade III – B. pahangi). Three of the 10 analogs of 6a (6c, d, j) were effective 
against T. muris and B. pahangi whereas 23a-c and 24a-c (analogs of 10a) had only a species-
specific effect with efficacy against the filarial nematode, B. pahangi. In addition, as evidenced by the 
IC50 values, two analogs (6c, d) were much more potent compared to 6a (Table S4) against both 
B. pahangi (14 and 11 vs. 96 µM) and T. muris (118 and 32 vs. 195 µM). Time- and species-
dependent IC50 values are provided in Figure S27. 
 The compounds 6l-o were designed (Figures 3 and 4) to incorporate a carboxylic acid, as 
observed from docking analyses to make an electrostatic or H-bonding interaction with His372 of 
CPT2 like that of the benzoic acid of 10a, 17a and 17b. In addition to the carboxylic acids (6n and 
6o), the methyl esters (6l and 6m) were prepared as prodrugs thought to increase penetration of the 
worm outer cuticle.  Interestingly, only the methyl esters 6l and 6m showed any noticeable activity, 
with the most active of the four, 6m, requiring 250 µM and 175 µM concentrations to inhibit motility for 
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 T. muris and B. pahangi, respectively, at 48 hours. The free acids had negligible activity on either B. 
pahangi or T. muris (Table S4), possibly indicating poor cuticle permeability.  
 
Differential activity is potentially related to worm cuticle membrane penetration and uptake 
One possible explanation for the differential phenotypic activity of the compounds tested 
among intestinal species may be differential penetration of the cuticle between species. 
Bioaccumulation assays (Figure S28-44) of P1, 6a and 10a by LC-MS of lysates of T. muris after 
incubation with these compounds clearly detected P1 and 6a using the 210 nm channel and MS 
identification of the parent compound, but not 10a (Table S6 and Figure S28-S44). This would 
support that activity in T. muris results from this differential uptake of these compounds into the worm. 
In B. pahangi, neither compound 6a nor 10a was observed at the incubation concentrations 
used, both having IC50 values less than 100 µM; however, 6f, which has negligible activity, was 
present in high quantities. P1 (and analogs P1a and P1b) was observed; however, it was observed 
near the limit of detection, likely due to low concentrations used and weak recovery. The pro-drug 
compounds 6l and 6m were observed in much higher abundance than their free-acid counterparts 6n 
and 6o, respectively, supporting the hypothesis that uptake into the cuticle may benefit by increasing 
hydrophobicity of the compounds.  
 
In vivo activity of Perhexiline in hookworm-infected hamsters 
To ascertain whether our newly discovered class of pan-nematode chokepoint inhibitors 
possessed therapeutic utility in parasitic nematodes, Syrian hamsters (Mesocricetus auratus) infected 
with A. ceylanicum were treated with PHX (P1) at 100 mg/kg per os.  Although the treatment had no 
marked effect on the worm load, there was a significant reduction in A. ceylanicum eggs/gram of 
feces compared to untreated control (Figure 5A and B). This result suggested that the target of P1 
(either a CPT isoform or another target) may interfere with reproduction in hookworms at the 
concentration resulting from this treatment or that generalized intoxication of the parasites in vivo led 
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 to a reduction in reproduction. Pertinent and consistent with the former, metabolic enzymes like CPT 
are essential for oocyte development in mammals,29 and beta-oxidation plays a critical role in egg 
production in schistosomes, a flatworm parasite of mammals.30 The observation that P1 causes 
significant impaired egg production is supported by the RNAseq based developmental gene 
expression profiles of CPTs in A. ceylanicum which shows lower expression of CPT1/2 in L4 female 
compared to adult female and compared to L4 male and adult males (Figure 5C and D). CPT 
expression in tissues of Ascaris suum (intestinal nematode large enough to perform facile tissue 
dissection) also shows much higher expression in ovary compared to both uterus in female worms 
and the seminal vesicle and testis in males (Figure S45; A. suum RNAseq normalized expression 
values are from Rosa et al, 2014).31 The in vivo screening results and the RNAseq expression profiles 
support the overall observation that the P1 target plays a critical role in egg production.   
 
CONCLUSIONS 
Nematode parasites have evolved over millions of years to occupy a wide variety of ecological 
and trophic niches. Nematoda is an ancient phylum with the estimated time since last common 
ancestors with other animal phyla being traced to the Cambrian explosion ~550 million years ago.32-33 
As the consequence of this complex natural history, discovery of drugs that exhibit activity against a 
broad spectrum of species of parasitic nematodes that are only very distantly related to each other is 
challenging. Nonetheless, there is a pressing need for novel, broadly effective anthelmintics, 
especially given that multiple concurrent infections occur in many regions.34 Here, starting with a 
single compound perhexiline (PHX) that has been reported to display pan-phylum potential as anti-
parasitic by Taylor et al. 2013,12 we identified diverse classes of chemical compounds that are 
effective against an array of divergent nematodes encompassing different modes of parasitism – 
intestinal and tissue-dwelling. These inhibitors display in vitro whole worm assay IC50 values similar to 
anthelmintics that are currently most commonly used.35 Notably, even though anthelmintic activity 
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 have not been previously attributed to these compounds, many of the prioritized compounds that we 
rationally selected for screening displayed significant anthelmintic activity against one or more 
species of nematodes.  
Herein, \we have shown that several series of previously known CPT modulators and newly 
designed compounds significantly affect the motility and viability of several types of parasitic worms in 
phenotypic assays of worm motility. It remains unclear whether the relative differences among 
species is a result of variable inhibition of the nematode CPT enzymes or is due to differential outer 
membrane penetration of the worms. Since, we only performed phenotypic screening on whole 
worms, it is plausible that one or more of these new chemical series of nematode inhibitors do not 
target CPTs and the effect is derived from other biological targets or activities. However, our findings 
from drug bioaccumulation screening suggest that some inactive analogs are incapable of penetrating 
the cuticle of the nematode. This knowledge can be directed at improving uptake of inhibitors through 
the neamtode cuticle and used to optimize the compounds for potency.  
To conclude, we report the discovery of multiple series of small molecules as novel 
anthelmintics with pan-phylum anti-nematode activity. Following a rationally guided repurposing 
strategy of small molecule human CPT inhibitors, we have successfully identified several new 
chemical classes of pan-nematode inhibitors. Since our data were generated via phenotypic 
screening, additional investigation is needed to identify their mechanism of action. It is possible that 
the different chemical series might have diverse targets, some of which may include nematode CPT 
enzymes. Nevertheless, our results from this study now enable and facilitate the optimization of these 
lead novel small molecule inhibitors as innovative drugs to treat a variety of debilitating diseases 
caused by parasitic worms. 
 
METHODS 
Ethics statement 
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 All animal experiments were carried out under protocols approved by University of 
Massachusetts Medical School (UMMS; A-2483 and A-2484) Institutional Animal Care and Use 
Committees (IACUC).  All housing and care of laboratory animals conformed to the National Institutes 
of Health (NIH) Guide for the Care and Use of Laboratory Animals in Research (see 18-F22) and all 
requirements and all regulations issued by the United States Department of Agriculture (USDA), 
including regulations implementing the Animal Welfare Act (P.L. 89-544) as amended (see 18-F23). 
Euthanasia was accomplished by CO2 asphyxiation, followed by bilateral pneumothorax. 
 
Identifying known small molecule CPT modulators 
CPT orthologs were identified using orthoMCL36 over predicted proteomes of 23 species. The 
proteomes selected belonged to 14 nematodes – including STHs, filariids and strongylids – and nine 
outgroup species (Table S1). An inflation factor of 1.5 was used. CPT genes of C. elegans were used 
to identify CPT orthologs in the other species. Normalized A. ceylanicum CPT expression levels for 
Fig. 5C and 5D were extracted from developmental global expression profile table available at 
Nematode.net37 and normalized A. suum CPT expression levels for Figure S1 were extracted from 
Rosa et al, 2014.31   
 CPT orthologs among the target proteins in ChEMBL database v18 were identified using 
BLAST (e-10, 50% identity) identifying 105 ChEMBL compounds targeting these proteins (Table S2). 
Compound clustering was accomplished based on structural similarity using FP2 fingerprints in Open 
Babel (v2.3).38 The physicochemical score was assigned based on an approach reported 
previously,12 with a minimum score of 4 being required for selection. Information on commercial 
availability of test compounds was sourced from the ZINC database.39  
 Homology models were built for four worm and three mammalian host species using Molecular 
Operating Environment software (Chemical Computing Group, Montreal, version 2014.09). CPT 
sequences from the nematodes T. muris, A. ceylanicum, C. elegans, S. stercoralis and the mammals 
M. musculus, M. auratus, and H. sapiens, were aligned with the crystal structures from R. norvegicus 
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 CPT2 (2FW3).40 This structure includes the ligand teglicar41 in the binding site. The homology models 
were built individually, with the teglicar atoms included to maintain reasonable binding site geometry. 
Each model was energy minimized using the AMBER10 force field.42 Resulting models were 
compared to several other rat CPT2 crystal structures (2DEB, 2FYO, 2H4T, 4EP9, 4EPH, 4EYW) 
with no significant differences in the region of the binding site. Ligand docking to any of the models 
was done using FRED (OpenEye Scientific Software, Santa Fe, version 3.0.1), followed by energy 
minimization in the AMBER10 force field.   
 
Compound screening with intestinal nematodes 
A. ceylanicum: In vitro assays were carried out as previously described.35 Three adult worms 
were manually sorted into each wells of 96-well plate, containing culture medium and the test drug (4 
wells/test drug).  Primary CPT inhibitors were tested against hookworm at 1, 3, 10, 40 and 80 µg/ml in 
1% DMSO. Analogs of 6a and 10a were tested at 250 µMand 125 µM. Worms were scored for 
motility after 24 hours of incubation at 37°C and 5% CO2. 
T. muris: In vitro assays were carried out as described.35 Four worms were manually sorted 
into each well of 24-well plates (3 wells/ test drugs). Primary CPT inhibitors were tested against 
whipworms at 40 and 80 µg/ml and the analogs of 6a and 10a were tested at 250 µMand 125 µM. 
Worms were scored for motility after 48 hours of incubation at 37°C and 5% CO2. IC50 
determinations were conducted at 500 µM, 250 µM, 125 µM , 62.5 µM, 31.25 µM, 15.6 µM, 7.8 µM, 
3.9 µM, 1.9 µM, 0 µM. IC50 values at 48 hours were used to establish a non-linear regression using 
Prism 7 (Graphpad, La Jolla, CA). All T. muris IC50s listed displayed R2 values ≥0.8. 
H. polygyrus: 4 weeks old Swiss Webster mice (females) were infected by stomach gavage 
with infective L3 of H. polygyrus, 15 days post infection parasites were harvested from the small 
intestine and four worms were manually sorted into each well of 96-well plates (three wells/ test 
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 drugs) containing nematode culture medium and test drugs at 80 and 40 µg/ml in 1% DMSO. Worms 
were scored for motility after 72 hours of incubation at 37°C and 5% CO2.  
N. brasiliensis: 5 weeks old laboratory rats were infected with iL3 of N. brasiliensis by the 
subcutaneous route. Six days post infection, the rats were euthanized and parasites were harvested 
from the small intestine and four worms were manually sorted into each well of 96-well plates (four 
wells/ test drugs) containing nematode culture medium and test drugs at 80 and 40 µg/ml in 1% 
DMSO. Worms were scored for motility after 48 hours of incubation at 37°C and 5% CO2.  
Ex vivo drug activity was determined using the standard motility index ranging from 0-3 as 
previously described.35 Motility index of 3 were given to vigorous worms, 2 for motile worms, 1 for 
motile after stimulation by touching, and 0 for dead worms. 
 
Compound screening with the filarial nematode B. pahangi 
Adult female B. pahangi worms were obtained from Dr. Brenda Beerntsen, University of 
Missouri, Columbia, MO. Individual females were placed in each well of a 24-well plate in culture 
medium (RPMI-1640 with 25 mM HEPES, 2.0 g/L NaHCO3, 5% heat inactivated FBS, and 1X 
Antibiotic/Antimycotic solution). Excess medium was removed, leaving 500 µL in each well. 
Fresh powders of the seven known CPT inhibitors that were synthesized (6a, 10a-c and 17a-
b) were dissolved in DMSO (Fisher Scientific, Fair Lawn, NJ). Initial screening of the compounds was 
performed at 100 µM  and at 20 µM. Four worms were used as replicates at each concentration. 
Worms treated with 1% DMSO only served as the negative control. The cultures were maintained at 
37°C, 5% CO2 incubator for seven days; the duration of the assay. 
The Worminator, a visual imaging software system developed and described previously was 
used to determine the effect of each treatment on worm motility.43 Movements of individual worms 
were calculated by determining the number of pixels displaced per second per well. Worm 
movements were averaged over the time of recording (60 seconds) and mean movement units 
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 (MMUs) were determined for individual worms. Percent inhibition of motility was calculated by dividing 
the MMUs of the treated worms by the average MMUs of the 1% DMSO treated control worms, 
subtracting the value from 1.0, flooring the values to zero and multiplying by 100%. Videos of the 
worms during the assay were recorded on days 0, 1, 2, 3, and 6 of the incubation. Compounds 
showing ≥75% inhibition of motility at either concentration on day 3 of the assay were investigated 
further using IC50 assay. Compounds 6a and 10a at 100µM fit this criterion, inhibiting worm motility 
95% and 100%, respectively, on day 3.  IC50 determinations were conducted at 100 µM, 30 µM, 10 
µM, 3 µM , 1 µM, 0.3 µM. Worms were treated in the same fashion as above and motility was 
measured each day for three days using the Worminator. IC50 values on day 2 was used to establish 
a non-linear regression curve fit, using Prism 7 (Graphpad, La Jolla, CA). All Brugia IC50s listed in 
Table S4 all displayed R2 values ≥0.8. 
 
Bioaccumulation assays 
T. muris: Twelve adult T. muris worms were placed into three worms/well. The wells contained the 
drug at a final concentration of 100 µM in 1% DMSO. After 6 hours of incubation, the worms were 
placed into clean plates containing saline and washed twice. This was followed by three more washes 
using 0.1% SDS to remove drugs from the surface. The worms were then placed into an Eppendorf 
tube and washed twice using saline and centrifuged to form a pellet, which was stored overnight at -
20°C. At the time of assay, the worms were frozen in liquid Nitrogen, crushed using pestles and 
incubated with 100 µL of 1x lysis buffer with proteinase K for 60 min at 60°C.  Two µL of the worm 
digestant was used to measure the total protein content using BCA protein kit. The proteins from the 
remaining digestant were precipitated using 100 µL of acetonitrile. The supernatant (~180 µL) was 
stored at -80°C.  The lysates were analyzed for levels of each individual compound by HPLC/MS 
analysis. DMSO was used as the negative control while P1, which is known to be membrane 
permeable, was used as the positive control.  
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 Lysates were analyzed on a Hewlett Packard Series 1100 HPLC, using a Sunfire C18 3.5 µm 
pore-size, 4.6 x 50 mm column. Samples were injected with 10 µL of volume with a flow rate of 1 
mL/min, and solvent system of H2O (0.01% TFA) and acetonitrile (0.05% TFA). Gradient was 0→5 
minutes: 5-95% linear increase acetonitrile, 5→6 minutes 95% acetonitrile hold, 6→7 minutes 95-5% 
linear decrease acetonitrile. Elution was monitored by 210 and 254 nm UV-absorption and by MS. MS 
conditions were drying gas 12 L/min, drying gas temperature 350° C, nebulizer psig 55-60, and 
capillary voltage 4000 V. Compound presence was evaluated by extracting [M+H]+ or [M+Na]+ of 
parent compound mass. 
B. pahangi: Adult female B. pahangi worms were prepared for in vitro culture as described above and 
treated in vitro for 72 hours. Upon collection worms were washed twice in 0.1% SDS, followed by 1 
wash in culture media, then frozen in culture media at -20o C. To prepare lysates for bioaccumulation 
assays, worms were thawed on ice, media was removed, and three to four worms were pooled 
together. Worms were then washed once with PBS, frozen in liquid nitrogen and crushed with 
pestles. Lysates were prepared as described for T. muris above, with the exception that worms were 
incubated at 60o C for 5 hours. 
 
Perhexiline A. ceylanicum in vivo assay 
Experiments were conducted essentially as previously described.35, 44 Five weeks old golden 
Syrian hamsters were infected with 100 iL3 of A. ceylanicum. Infected rodents were grouped based 
on the fecal egg count on day 18 post infection. One group was treated with single oral dose of 100 
mg/kg Perhexiline (1) whereas the other group (control) was dosed only with water. Fecal samples 
were collected 20 days post infection (p.i) for fecal egg count. On day 21 p.i., the hamsters were 
euthanized and the small intestine opened longitudinally. Adult parasites within the intestine were 
counted under a dissecting microscope.  
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 COMPOUND SYNTHESIS 
General Methods 
Starting materials, reagents, and solvents were purchased from commercial vendors unless 
otherwise noted. In general, anhydrous solvents were used for carrying out all reactions. 1H and 13C 
NMR spectra were measured on a Varian 400 MHz NMR instrument equipped with an auto sampler. 
The chemical shifts were reported as δ ppm relative to TMS using residual solvent peak as the 
reference unless otherwise noted. The following abbreviations denote the peak multiplicities: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad. All reactions were monitored by 
thin layer chromatography (TLC) carried out on either Merck silica gel plates (0.25 mm thick, 60F254) 
and visualized by using UV (254 nm) or dyes such as phosphomolybdic acid. Silica gel 
chromatography was carried out on a Teledyne ISCO CombiFlash purification system using pre-
packed silica gel columns (4 g-24 g sizes).  
 
General procedures 
General procedure for compounds 6a and 6f: Method A 
Compound 4a45 (0.180 g, 0.52 mmol) was dissolved in trifluoroacetic acid (1 mL), stirred 1 h, then 
concentrated in vacuo to provide intermediate 5a, which was dissolved in anhydrous DCM (2 mL) and 
the solution was bubbled with argon 2 min, then triethylamine (0.29 mL, 2.1 mmol) and DMAP (0.006 
g, 0.05 mmol) were added, followed by phenoxyacetyl chloride (0.072 mL, 0.52 mmol). The mixture 
was stirred 24h at RT, then washed with water, then brine, dried with Na2SO4, and concentrated in 
vacuo, after which it was purified by silica gel chromatography with ethyl acetate/hexanes 
combinations as eluent, giving rise to the title compound 6a. 
 
General procedure for compounds 6(b-e) & 6(g-k): Method B 
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 CDI (66 mg, 0.4 mmol) was added into a solution of 2-phenoxyacetic acid (31 mg, 0.2 mmol) in DCM 
(2 mL) and solution was stirred for 30 min at room temperature; thereafter, solution of (R)-2-
(piperidin-2-yl)-4-(pyridin-2-yl, 5a45 (50 mg, 0.2 mmol) in DCM (1 mL) was added and the reaction 
solution stirred for 24h. Progress of the reaction was monitored by TLC and upon completion of the 
reaction, reaction mass diluted with DCM (10 mL), washed with 10% citric acid, followed by saturated 
NaHCO3 and brine. The organic layer was dried over anhydrous Na2SO4. Solvent was evaporated 
under reduced pressure and the crude compound was subjected for column chromatography. 
 
General procedure for compounds 6(l-m): Method C 
To a solution of 2-phenoxy acetic acid (120 mg, 0.57 mmol), there was added HOBt (231 mg, 1.71 
mmol) and EDC (265 mg, 1.71 mmol, 3 eq) at 0°C in 20 mL of THF, and allowed to stir for 15 
minutes. To this solution there was then added the amine 5a (135 mg, 0.57 mmol) and triethylamine 
(99 µL, 0.7 mmol). The solution was allowed to stir overnight and reach room temperature. The 
reaction was then diluted with EtOAc, and washed with 1M HCl, brine, and dried over Na2SO4. The 
ester was purified by silica gel column chromatography using EtOAc/hexanes to provide the 
compounds 6(l-m). The methyl ester 6(l-m) was dissolved in methanol/water (1:1 v/v) and three 
equivalents of LiOH were added and the solution stirred until the methyl ester was fully hydrolyzed. 
The majority of the methanol was removed in vacuo and the resulting solution was extracted with 
EtOAc, dried with Na2SO4, and concentrated under reduced pressure. The crude compounds were 
purified by silica gel column chromatography using EtOAc/hexanes to provide the compounds 6(m-
o). 
 
(R)-2-phenoxy-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6a) 
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 Compound synthesized as per method A, white solid with 170 mg in 86% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 8.94 (d, J = 5.5 Hz, 1 H), 8.57 (s, 1 H), 8.31-8.23 (m, 1 H), 8.14 (t, J = 7.4 Hz, 1 H), 
7.56 (t, J = 6.3Hz, 1 H), 6.05 (d, J = 4.7 Hz, 1 H), 4.76 (s, 2 H), 3.91 (d, J = 13.3 Hz, 1 H), 3.21 (t, J = 
12.7 Hz, 1 H), 2.51 (d, J = 13.7 Hz, 1 H), 1.93-1.79 (m, 1 H), 1.77-1.58 (m, 3 H), 1.58-1.35 (m, 1 H) 
(rotamers); LCMS (ESI): found [M + H]+, 380.3. 
 
(R)-2-([1,1'-biphenyl]-4-yloxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6b). 
 
Compound synthesized as per method B, white solid with 37 mg in 40% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.15 (br. s., 1 H), 8.63-8.52 (m, 1 H), 8.23 (d, J = 7.8 Hz, 1 H), 7.52 (br. s., 4 H), 7.47 
(br. s., 1 H), 7.45-7.36 (m, 3 H), 7.36-7.28 (m, 1 H), 7.08 (d, J = 8.2 Hz, 2 H), 6.99 (d, J = 8.6 Hz, 1 
H), 6.14 (d, J = 4.3 Hz, 1 H), 4.88 (d, J = 3.1 Hz, 2 H), 3.98 (d, J = 16.8 Hz, 1 H), 3.46 -3.30 (m, 1 H), 
2.72-2.52 (m, 1 H), 2.29- 2.01 (m, 3 H), 1.94 (dd, J = 18.2, 6.1 Hz, 2 H), 1.80 (br. s., 3 H), 1.72 (br. s., 
1 H),1.68-1.49 (m, 2 H), 1.35-1.17 (m, 2 H), 0.93-0.77 (m, 1 H)(rotamers); LCMS (ESI): found [M + 
H]+, 456.3. 
 
(R)-2-(naphthalen-1-yloxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6c). 
 
Compound synthesized as per method B, white solid with 32 mg in 41% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.14 (br. s., 1 H), 8.57 (br. s., 1 H), 8.32 (d, J = 7.4 Hz, 1 H), 8.24-8.10 (m, 1 H), 7.83 
(d, J = 6.7 Hz, 1 H), 7.60-7.45 (m, 4 H), 7.45-7.31 (m, 4 H), 6.95 (d, J = 6.3 Hz, 1 H), 6.17 (br. s., 1 
H), 5.11-4.94 (m, 2 H), 4.21-4.00 (m, 1 H), 3.49-3.27 (m, 1 H), 2.70-2.56 (m, 1 H), 1.83-1.67 (m, 3 H), 
1.67-1.46 (m, 1 H), 1.27 (br. s., 1 H)(rotamers); LCMS (ESI): found [M + H]+, 430.3. 
 
2-(naphthalen-2-yloxy)-1-((2R)-2-(4-(pyridin-2-yl)-4,5-dihydrothiazol-2-yl)piperidin-1-yl)ethan-1-
one (6d). 
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 Compound synthesized as per method B, white solid with 18 mg in 41% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.28 (br. s., 1 H), 8.71 (d, J = 4.3 Hz, 1 H), 8.57 (d, J = 8.2 Hz, 1 H), 7.84-7.74 (m, 2 H), 
7.74-7.52 (m, 4 H), 7.48-7.29 (m, 3 H), 7.26-7.10 (m, 3 H), 6.15 (d, J = 5.1 Hz, 1 H), 4.96 (s, 2 H), 
4.08 (d, J = 13.3 Hz, 1 H), 3.35 (t, J = 12.7 Hz, 1 H), 2.65-2.51 (m, 1 H), 2.03 -1.87 (m, 1 H), 1.86-
1.68 (m, 3 H), 1.68-1.49 (m, 1 H)(rotamers); LCMS (ESI): found [M + Na]+, 430.3. 
 
2-(4-((3R,5R,7R)-adamantan-1-yl)phenoxy)-1-((R)-2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-
yl)ethan-1-one (6e). 
 
Compound synthesized as per method B, white solid with 24 mg in 46% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.14 (br. s., 1 H), 8.58 (br. s., 1 H), 8.20 (d, J = 7.0 Hz, 1 H), 7.52 (s, 1 H), 7.42-7.32 
(m, 1 H), 7.23 (d, J = 7.8 Hz, 1 H), 6.95 (d, J = 8.2 Hz, 1 H), 6.87 (d, J = 7.4 Hz, 1 H), 6.12 (br. s., 1 
H), 4.80 (d, J = 7.4 Hz, 2 H), 3.95 (d, J = 12.9 Hz, 1 H), 3.43-3.28 (m, 1 H), 2.62 (d, J = 11.7 Hz, 1 H), 
2.09 (br. s., 4 H), 1.97-1.80 (m, 10H), 1.26 (br. s., 5 H), 0.88 (d, J=10.2 Hz, 1 H)(rotamers); LCMS 
(ESI): found [M + Na]+, 514.4. 
 
(R)-2-(4-methoxyphenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6f). 
 
Compound synthesized as per method A, white solid with, 176 mg in 86% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 7.83 (d, J = 8.2 Hz, 2 H), 7.37-7.27 (m, 2 H), 7.26-7.20 (m, 1 H), 7.05-6.91 (m, 5 H), 
6.12 (br. s., 1 H), 4.94-4.76 (m, 2 H), 3.91 (d, J = 13.3 Hz, 1 H), 3.86 (s, 3 H), 3.38 (t, J = 13.1 Hz, 1 
H), 2.62 (d, J = 12.1 Hz, 1 H), 2.08-1.91 (m, 1 H), 1.84 (d, J = 14.1 Hz, 1 H), 1.73 (d, J = 12.5 Hz, 2 
H), 1.65-1.56 (m, 1 H), 1.56-1.39 (m, 1 H)(rotamers); LCMS (ESI): found [M + H]+, 410.4. 
 
(R)-2-(4-cyclohexylphenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6g). 
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 Compound synthesized as per method B, white solid with 21 mg in 45% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.13 (br. s., 1 H), 8.58 (br. s., 1 H), 8.28-8.03 (m, 1 H), 7.52 (br. s., 1 H), 7.36 (br. s., 1 
H), 7.22 -7.02 (m, 2 H), 7.02-6.88 (m, 1 H), 6.85 (br. s., 1 H), 6.12 (br. s., 1 H), 4.76 (br. s., 2 H), 3.96 
(d, J = 9.0 Hz, 1 H), 2.63 (d, J = 10.6 Hz, 1 H), 2.54-2.25 (m, 1 H), 1.83 (br. s., 5 H), 1.76 (br. s., 4 H), 
1.37 (br. s., 6 H), 1.26 (br. s., 6 H), 0.87 (d, J = 10.6 Hz, 1 H)(rotamers); LCMS (ESI): found [M + H]+, 
462.4. 
 
(R)-2-(4-benzylphenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6h). 
 
Compound synthesized as per method B, white solid with 24 mg in 50% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm9.34 (br. s., 1 H), 8.79-8.64 (m, 2 H), 7.85-7.74 (m, 1 H), 7.67 (s, 1 H), 7.35-7.29 (m, 1 
H), 7.25-7.02 (m, 5 H), 6.93 (d, J = 8.2 Hz, 1 H), 6.11 (d, J = 4.3 Hz, 1 H), 4.81 (br. s., 2 H), 3.99 (d, J 
= 14.1 Hz, 1 H), 3.95-3.85 (m, 2 H), 3.27 (t, J = 12.9Hz, 1 H), 2.55 - 2.68 (m, 1 H), 2.11-1.87 (m, 1 H), 
1.83-1.53 (m, 4 H)(rotamers); LCMS (ESI): found [M + H]+, 470.4. 
 
(R)-2-((4'-methyl-[1,1'-biphenyl]-4-yl)oxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-
one (6i). 
 
Compound synthesized as per method B, white solid with 12 mg in 42% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 9.13 (br. s., 1 H), 8.56 (br. s., 1 H), 8.23-8.13 (m, 1 H), 7.59 (br. s., 1 H), 7.51 (d, J = 
7.0 Hz, 3 H), 7.47-7.39 (m, 3 H), 7.39-7.30 (m, 2 H), 7.26-7.15 (m, 3 H), 7.06 (d, J = 7.4 Hz, 1 H), 
7.03-6.88 (m, 1 H), 6.14 (br. s., 1 H), 4.87 (br. s., 2 H), 3.98 (d, J = 5.5 Hz, 1 H), 3.44-3.32 (m, 1 H), 
2.77-2.53 (m, 1 H), 2.39 (br. s., 4 H), 1.91-1.67 (m, 3 H), 0.96-0.77 (m, 4H)(rotamers); LCMS (ESI): 
found [M + H]+, 470.4. 
 
(R)-2-(4-(pyridin-2-yl)phenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6j) 
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Compound synthesized as per method B, white solid with 50 mg in 41% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm9.13 (br. s., 1 H), 8.66 (br. s., 1 H), 8.56 (br. s., 1 H), 8.17 (d, J = 6.7 Hz, 1 H), 7.85-8.01 
(m, 2 H), 7.80-7.62 (m, 2 H), 7.52 (br. s., 1 H), 7.35 (br. s., 1 H), 7.21 (br. s., 1 H), 7.10 (d, J = 7.8 Hz, 
1 H), 7.02 (d, J = 7.0 Hz, 1 H), 6.13 (br. s., 1 H), 4.08-3.90 (m, 1 H), 3.38 (t, J = 12.7 Hz, 1 H), 2.73-
2.56 (m, 1 H), 2.03 (d, J = 18.4 Hz, 2 H), 1.97-1.86 (m, 1 H), 1.78 (br. s., 2 H), 1.70 (br. s., 1 H), 1.65-
1.45 (m, 1 H), 1.26 (br. s., 2 H)(rotamers); LCMS (ESI): found [M + H]+, 457.3. 
 
(R)-1-(2-(4-(naphthalen-2-yl)thiazol-2-yl)piperidin-1-yl)-2-phenoxyethan-1-one (6k) 
N
S
N
O
O
 
Compound synthesized as per method B, white solid with 20 mg in 50% yield; 1H NMR (400 MHz, 
CD3Cl) δ ppm 8.45 (s, 1 H), 8.03 (d, J = 8.6 Hz, 1 H), 7.93-7.82 (m, 4 H), 7.53-7.43 (m, 2 H), 7.30-
7.20 (m, 1 H), 7.14 (t, J = 7.6 Hz, 1 H), 7.02 (d, J = 7.8 Hz, 1 H), 6.95 (d, J = 7.8 Hz, 2 H), 6.08 (d, J = 
4.3 Hz, 1 H), 5.07-4.91 (m, 2 H), 3.95 (d, J = 13.7 Hz, 1 H), 3.41 (t, J = 13.1 Hz, 1 H), 2.72 - 2.47 (m, 
1 H), 2.03-1.90 (m, 1 H), 1.83-1.61 (m, 4 H)(rotamers); LCMS (ESI): found [M + H]+, 429.3 
 
(R)-2-((4-methylbenzoate)phenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one 
(6l) 
 
Compound synthesized as per method C, white solid with 140 mg in 65% yield. 1H NMR (400 MHz, 
CD3OD)δ ppm: 9.39-9.12 (m, 1H), 9.04-8.81 (m, 1H); 8.77-8.66 (m, 1H), 8.39-8.21 (m, 1H), 8.06-7.71 
(m, 3H), 7.10-6.84 (m, 2H), 6.10-5.20 (m, 1H), 5.10 (m, 2 H), 4.50-3.90 (m, 1H), 3.87-3.77 (m, 3 H), 
3.30 (m, 1 H),  2.98-1.46 (m, 7 H)(rotamers); LCMS (ESI): found [M+H]+, 438.3  
 
(R)-2-(3-methylbenzoatephenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one 
(6m) 
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Compound synthesized as per method C, white solid with 135 mg, 63% yield. 1H NMR (400 MHz, 
CD3OD)δ ppm 9.17-9.02 (m, 1H), 8.53-8.43 (m, 1H), 8.35 (m, 1 H), 8.11-7.96 (m, 1 H),  7.67-7.58 (m, 
1 H), 7.56-7.44 (m, 2H), 7.42-7.11 (m, 2 H), 6.15-5.6 (m, 1 H), 5.00 (m, 2H), 4.0-4.50 (m, 1H), 3.91-
3.79 (m, 3H), 3.40-2.50-3.4 (m, 2H), 2.04-1.17 (m, 7 H)(rotamers); LCMS (ESI): found [M+H]+, 438.3  
 
(R)-2-((4-benzoic acid)phenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6n) 
 
Compound synthesized as per method C, white solid with 43 mg, 88% yield. 1H NMR (400 MHz, 
CD3OD) δ ppm 9.30-9.01 (m, 1 H), 8.85-8.49 (m, 2 H), 8.28-8.05 (m, 1 H), 7.90-7.61 (m, 3 H), 7.10-
6.73 (m, 2 H), 6.13-5.51 (m, 1 H), 5.00 (m, 2 H), 4.54-3.77 (m, 1 H), 3.45-2.72 (m, 1 H), 2.64-1.32 (m, 
7 H) (rotamers); LCMS (ESI): found [M+H]+, 424.3 
 
(R)-2-((3-benzoic acid)phenoxy)-1-(2-(4-(pyridin-2-yl)thiazol-2-yl)piperidin-1-yl)ethan-1-one (6o) 
 
Compound synthesized as per method C, white solid with 35 mg, 72% yield. 1H NMR (400 MHz, 
CD3OD) δ ppm 9.23-8.99 (m, 1 H), 8.64-8.43 (m, 1 H), 8.43-8.20 (m, 1 H), 8.06-7.99 (m, 1 H), 7.95-
7.81 (m, 1 H), 7.87-7.69 (m, 1 H), 7.67-7.59 (m, 1 H), 7.58-7.43 (m, 3 H), 7.43-7.12 (m, 2 H), 6.20-
5.51 (m, 1 H), 5.00 (m, 2 H), 4.60-3.90 (m, 1 H), 3.45-2.60 (m, 1 H), 1.86-0.79- (m, 8 H) (rotamers); 
LCMS (ESI): found [M+H]+, 424.3 
 
General procedure for compounds 9(a-c): Method D 
Under nitrogen atmosphere, dry DCM (7.5 mL) was added to a flask containing methyl 3-
aminobenzoate (0.200 g, 1.3 mmol), then pyridine (0.41 mL, 5.1 mmol) was added. 3,4-
dichlorobenzenesulfonyl chloride (0.16 mL, 1.0 mmol) was added dropwise, then the solution was 
stirred for 3 h at RT. The mixture was poured into excess water and extracted with DCM. The organic 
layers were combined, washed with aqueous 1N HCl, dried with Na2SO4, and concentrated in vacuo. 
The resulting residue was purified by silica gel chromatography with hexane/ethyl acetate 
combinations as eluent, giving rise to methyl 3-((3,4-dichlorophenyl)sulfonamido)benzoate (0.262 g) 
in 71% yield. MS (ESI): found [M + H]+, 360.1. This material was dissolved in methanol/water (1/1 v/v) 
and three equivalents of LiOH were added and the solution was stirred until the methyl ester was fully 
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 hydrolyzed. The majority of methanol was removed in vacuo and the resulting solution was extracted 
with EtOAc, dried with Na2SO4, and concentrated in vacuo, giving rise to 3-((3,4-
dichlorophenyl)sulfonamido)benzoic acid 9a. 
 
3-((3,4-dichlorophenyl)sulfonamido)benzoic acid (9a) 
 
Compound synthesized as per method D, white solid with 189 mg in 75% yield; 1H NMR (400 MHz, 
CDCl3) δ ppm 7.85-7.79 (m, 1H), 7.75-7.69 (m, 2H), 7.42 (d, J = 8.61 Hz, 2H), 7.40-7.34 (m, 1H), 
7.03 (s, 1H); LCMS (ESI): found [M + H]+, 346.2. 
 
3-((4-chlorophenyl)sulfonamido)benzoic acid (9b) 
 
Compound synthesized as per method D, white solid with 155 mg in 80% yield; 1H NMR (400 MHz, 
CDCl3) δ ppm 7.86-7.78 (m, 1H), 7.75-7.65 (m, 3H), 7.42 (d, J = 8.61 Hz, 2H), 7.39-7.35 (m, 1H), 
7.02 (s, 1H); LCMS (ESI): found [M + Na]+, 334.2. 
 
3-((5-chloro-2-methoxyphenyl)sulfonamido)benzoic acid (9c) 
 
Compound synthesized as per method D, white solid with 125 mg in 77% yield; 1H NMR (400 MHz, 
CDCl3) δ ppm 7.81 (d, J = 2.74 Hz, 1H), 7.77 (d, J = 7.43 Hz, 1H), 7.66 (s, 1H), 7.38 - 7.47 (m, 2H), 
7.30-7.36 (m, 1H), 7.21 (s, 1H), 6.95 (d, J = 8.61 Hz, 1H), 3.90 (s, 3H); LCMS (ESI): found [M + Na]+, 
364.2. 
 
General procedure for compounds 10(a-c): Method E 
Under nitrogen atmosphere, anhydrous THF (3 mL) was added to a flask containing 9a (0.130 g, 0.38 
mmol) and the mixture was stirred in an ice/brine bath for 20 min, then 4-methylmorpholine (0.04 mL, 
0.38 mmol) and isopropyl chloroformate (1.0 M in THF, 0.38 mL) were added and the solution was 
stirred an additional 10 min. Anhydrous DMF (1.5 mL) containing methyl 4-aminobenzoate (0.057 g, 
0.38 mmol) was added and the mixture was stirred in an ice/brine bath for 45 min, then removed and 
allowed to warm to RT while being stirred over another 2 h. The mixture was heated to 50oC 
overnight, then cooled and concentrated in vacuo. Excess water was added and the mixture was 
extracted with EtOAc (2x5mL), combined dried ethyl acetate dried over anhydrous Na2SO4, and 
concentrated in vacuo. The resulting residue was purified by silica gel chromatography with 
hexane/ethyl acetate combinations as eluent, giving rise to methyl 4-(3-((3,4-
dichlorophenyl)sulfonamido)benzamido)benzoate (0.082 g) in 46% yield. MS (ESI): found [M + H]+, 
479.2. This material was dissolved in methanol/water (1/1 v/v) and LiOH (3.0 eq) were added and the 
solution was stirred until the methyl ester was fully hydrolyzed. The majority of methanol was 
removed in vacuo and the resulting solution pH~3 was adjusted with 3N aq. HCl and product was 
extracted with EtOAc (2x5mL), combined ethyl acetate washed with brine and dried over anhydrous 
Na2SO4, and concentrated in vacuo, then purified by HPLC (C18, 15*150 mm column; eluent: 
acetonitrile/water (0.05% TFA)), giving rise to the title compound 10a. 
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4-(3-((3,4-dichlorophenyl)sulfonamido)benzamido)benzoic acid (10a)
 
Compound synthesized as per method E, white solid with 15 mg in 19% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm 8.03-8.01 (m, 1 H), 8.01-7.98 (m, 1 H), 7.88 (d, J = 2.0 Hz, 1 H), 7.79-7.77 (m, 1 H), 
7.77-7.74 (m, 1 H), 7-67-7.63 (m, 2 H), 7-62-7.60 (m, 2 H), 7-57-7.53 (m, 2 H), 7.41-7.36 (m, 1 H), 
7.36-7.31 (m, 1 H); LCMS (ESI): found [M + Na]+, 467.1. 
 
4-(3-((4-chlorophenyl)sulfonamido)benzamido)benzoic acid (10b)
 
Compound synthesized as per method E, white solid with 30 g in 67% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm 8.036-7.97 (m, 2 H), 7.78-7.66 (m, 6 H), 7.65-7.59 (m, 1 H), 7.57-7.52 (m, 1 H), 7.48-
7.43 (m, 1H), 7.43-7.37 (m, 3 H), 7.36-7.28 (m, 3 H); LCMS (ESI): found [M + H]+, 431.3. 
 
4-(3-((3-chlorophenyl)sulfonamido)benzamido)benzoic acid (10c) 
 
Compound synthesized as per method E, white solid with 20 mg in 61% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm; 8.03-7.98 (m, 2 H), 7.82-7.78 (m, 2 H), 7.76 (d, J = 2.7 Hz, 1 H), 7-68-7.65 (m, 1 H), 
7.59 (ddd, J = 5.6, 3.2, 1.8 Hz, 1 H), 7.49 (dd, J = 9.0, 2.7 Hz, 1 H), 7.39-7.35 (m, 2 H), 7.12 (d, J = 
9.0 Hz, 1 H), 3.95 (s, 3 H); LCMS (ESI): found [M + H]+, 461.2. 
 
General procedure for compounds 14(a-b): Method F 
Under nitrogen atmosphere, dry DCM (5 mL) was added to a flask containing methyl indoline-6-
carboxylate 11a (0.150 g, 0.8 mmol), then pyridine (0.28 mL, 3.5 mmol) was added. 5-chloro-2-
methoxybenzenesulfonyl chloride (0.170 g, 0.7 mmol) was dissolved in dry DCM (5 mL), which was 
added drop wise to the flask, then the solution was stirred for 8h at RT. The mixture was poured into 
excess water and extracted with DCM. The organic layers were combined, washed with aqueous 1N 
HCl, dried with Na2SO4, and concentrated in vacuo. The resulting residue was purified by silica gel 
chromatography with hexane/ethyl acetate combinations as eluent, giving rise to methyl 1-((5-chloro-
2-methoxyphenyl)sulfonyl)indoline-6-carboxylate 13a (0.159 g) in 60% yield. MS (ESI): found [M + 
H]+, 382.2. This material was dissolved in methanol/water (1/1 v/v) and three equivalents of LiOH 
were added and the solution was stirred until the methyl ester was fully hydrolyzed. The majority of 
methanol was removed in vacuo and the resulting solution was extracted with EtOAc, dried with 
Na2SO4, and concentrated in vacuo, giving rise to 14a. 
 
1-((5-chloro-2-methoxyphenyl)sulfonyl)indoline-6-carboxylic acid (14a).  
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Compound synthesized as per method F, white solid with 124 mg in 81%; 1H NMR (400 MHz, CDCl3) 
δ ppm 8.07-8.04 (m, 1H), 8.01 (s, 1H), 7.68 (d, J = 7.83 Hz, 1H), 7.47-7.42 (m, 1H), 7.18 (d, J = 7.83 
Hz, 1H), 6.85 (d, J = 8.61 Hz, 1H), 4.11 (t, J = 8.61 Hz, 2H), 3.63 (s, 3H), 3.10 (t, J = 8.61 Hz, 2H); 
LCMS (ESI): found [M + Na]+, 390.2. 
 
4-(3-((5-chloro-2-methoxyphenyl)sulfonamido)benzamido)benzoic acid (14b) 
 
Compound synthesized as per method F, white solid with 165 mg in 83%; 1H NMR (400 MHz, CDCl3) 
δ ppm 8.10-8.04 (m, 1H), 8.02 (s, 1H), 7.70 (d, J = 7.81 Hz, 1H), 7.49-7.45 (m, 1H), 7.20 (d, J = 7.84 
Hz, 1H), 6.85 (d, J = 8.62 Hz, 1H), 4.11 (t, J = 8.61 Hz, 2H), 3.63 (s, 3H), 3.10 (t, J = 8.61 Hz, 2H), 
2.38 (s, 3H), 2.00-1.96 (m, 2H); LCMS (ESI): found [M + Na]+, 461.2. 
 
General procedure for compounds 17(a-b): Method G 
Under nitrogen atmosphere, anhydrous THF (3 mL) was added to a flask containing 14a (0.110 g, 
0.30 mmol) and the mixture was stirred in an ice/brine bath for 20 min, then 4-methylmorpholine (0.03 
mL, 0.30 mmol) and isopropyl chloroformate (1.0 M in THF, 0.30 mL) were added to the and the 
solution was stirred an additional 10 min. Anhydrous DMF (1 mL) containing methyl 4-aminobenzoate 
(0.045 g, 0.30 mmol) was added and the mixture was stirred in an ice/brine bath for 45 min., then 
removed and allowed to warm to RT while being stirred over another 30 min. The mixture was heated 
to 60 °C for 4 h, then cooled and concentrated in vacuo. Excess water was added and extracted with 
ethyl acetate (10 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The resulting 
residue was purified by silica gel chromatography with hexane/ethyl acetate combinations as eluent, 
giving rise to methyl 4-(1-((5-chloro-2-methoxyphenyl)sulfonyl)indoline-6-carboxamido)benzoate 16a 
(0.060 g) in 40% yield. This material was dissolved in methanol/water (1/1 v/v) and three equivalents 
of LiOH were added and the solution was stirred until the methyl ester was fully hydrolyzed. The 
majority of methanol was removed in vacuo and the resulting solution was extracted with EtOAc, 
dried with Na2SO4, and concentrated in vacuo, then purified by silica gel chromatography with 
methanol/dichloromethane combinations as eluent, giving rise to 45 mg of the title compound 17a. 
 
4-(1-((5-chloro-2-methoxyphenyl)sulfonyl)indoline-6-carboxamido)benzoic acid (17a) 
 
Compound synthesized as per method G, white solid with 45 mg in 77% yield; 1H NMR (400 MHz, 
DMSO-d6) δ ppm 12.76 (br. s., 1 H), 10.49 (s, 1 H), 7.95-7.89 (m, 3 H), 7.89-7.85 (m, 1 H), 7.73 (s, 1 
H), 7.69 (dd, J = 9.0,2.7 Hz, 1 H), 7.62 (dd, J = 7.8, 1.6 Hz, 1 H), 7.36 (d, J = 7.8 Hz, 1 H), 7.21 (d, J = 
9.0 Hz, 1 H), 4.10 (t, J = 8.6 Hz, 2 H), 3.66 (s, 3 H), 3.19-3.08 (m, 2H); LCMS (ESI): found [M + H]+, 
487.3. 
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4-(1-((2-methoxy-6-methylphenyl)sulfonyl)-1,2,3,4-tetrahydroquinoline-7-carboxamido)benzoic 
acid (17b) 
 
Compound synthesized as per method G, white solid with 69 mg in 82% yield; 1H NMR (400 MHz, 
DMSO-d6) δ ppm 10.12 (s, 1 H), 8.02 (s, 1 H), 7.71 (s, 1 H), 7.67 (d, J = 8.6 Hz, 2 H), 7.62-7.56 (m, 1 
H), 7.42 (d, J = 6.7 Hz, 1H), 7.27-7.17 (m, 3 H), 7.05 (d, J = 8.6 Hz, 1 H), 3.76 (dd, J = 6.5, 4.9 Hz, 2 
H), 3.55 (s, 3 H), 3.53 (s, 2 H), 2.73 (t, J = 6.5 Hz, 2 H), 2.29 (s, 3 H), 1.77-1.68 (m, 2 H); LCMS (ESI): 
found [M + H]+, 495.4. 
 
General procedure for compounds 23(a-c) and 24(a-c): Method H 
Aryl isocyanate 22a (1.48 mmol) was added into a solution of methyl 4-(3-aminobenzamido)benzoate 
21a46 (0.74 mmol)in DCM (20 mL) and the solution was stirred at room temperature and product 
slowly get precipitated from the solution, continued stirring for 24h. Filleted the product and washed 
with DCM (5mL) and pure compounds 23(a-c) were isolated. 
50% aq. NaOH solution (2 mL) was added into a solution of compounds 23a (100 mg, 0.23 mmol) in 
methanol (10 mL) and stir the solution at room temperature for 24h. Progress of the reaction 
monitored by TLC and upon completion of the reaction, neutralized the reaction solution with 3N aq. 
HCl under ice bath cooling and evaporated the solvent under reduced pressure. Diluted the crude 
mass with water (10 mL) and acidified the solution (pH ~ 2) by con. HCl under ice bath cooling, 
extracted product with Ethyl acetate (3x10mL) and washed the combined organic layer with brine 
(10mL). Dried the Ethyl acetate layer over anhydrous Na2SO4 and evaporated the solvent under 
reduced pressure and pure compounds 24a. 
 
methyl 4-(3-(3-(4-(dimethylamino)phenyl)ureido)benzamido)benzoate (23a) 
 
Compound synthesized as per method H, off-white solid with 90 mg in 56% yield; 1H NMR (400 MHz, 
DMSO-d6) δ ppm 10.56 (s, 1 H), 8.75 (s, 1 H), 8.35 (s, 1 H), 7.95 (br. s., 5 H), 7.67 (d, J = 8.2 Hz, 1 
H), 7.53 (d, J = 7.4 Hz, 1 H),7.43 (t, J = 7.8 Hz, 1 H), 7.28 (s, 2 H), 6.70 (d, J = 9.0 Hz, 2 H), 3.84 (s, 3 
H), 2.83 (s, 6 H);LCMS (ESI): found [M + H]+, 433.3. 
 
methyl 4-(3-(3-(4-nitrophenyl)ureido)benzamido)benzoate (23b). 
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 Compound synthesized as per method H, off-white solid with 200 mg in 84% yield; 1H NMR (400 
MHz, DMSO-d6) δ ppm 10.59 (s, 1 H), 9.50 (s, 1 H), 9.16 (s, 1 H), 8.20 (d, J = 9.0 Hz, 2 H), 8.03 (s, 1 
H), 7.90-8.00 (m, 5 H), 7.72 (d, J = 9.0 Hz, 3 H), 7.62 (d, J = 7.8 Hz, 1 H), 7.49 (t, J = 8.0 Hz, 1 H), 
3.84 (s, 3 H); LCMS (ESI): found [M + H]+, 435.3. 
 
methyl 4-(3-(3-(3,4-dichlorophenyl)ureido)benzamido)benzoate (AM1079-23c). 
N
H
H
N
O
CO2Me
HN
O
Cl
Cl
 
Compound synthesized as per method H, off-white solid with 120 mg in 35% yield; 1H NMR (400 
MHz, DMSO-d6) δ ppm 10.58 (s, 1 H), 9.07 (s, 2 H), 8.03-7.86 (m, 7 H), 7.69 (d, J = 7.8 Hz, 1 H), 
7.59 (d, J = 7.8 Hz, 1 H), 7.53 (d, J = 8.6 Hz, 1 H), 7.47 (t, J = 7.8 Hz, 1 H), 7.36 (d, J = 9.0 Hz, 1 H), 
3.84 (s, 3 H); LCMS (ESI): found [M + H]+, 459.3. 
 
4-(3-(3-(4-(dimethylamino)phenyl)ureido)benzamido)benzoic acid (24a) 
 
Compound synthesized as per method H, yellow solid with 10 mg in 50% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm 8.07-7.99 (m, 3 H), 7.85 (d, J = 8.6 Hz, 2 H), 7.68-7.58 (m, 5 H), 7.50-7.44 (m, 1 H), 
7.39 (br. s., 1H), 3.20 (br. s., 6 H); LCMS (ESI): found [M + H]+, 419.3. 
 
4-(3-(3-(4-nitrophenyl)ureido)benzamido) benzoic acid (24b). 
 
Compound synthesized as per method H, white solid with 10 mg in 50% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm 8.22 (m, J = 9.4 Hz, 2 H), 8.06-8.00 (m, 3 H), 7.85 (m, J = 8.6 Hz, 2 H), 7.74-7.68 (m, 
4 H), 7.63 (d ,J = 7.8 Hz, 1 H), 7.49 (t, J = 7.8 Hz, 1 H); LCMS (ESI): found [M + H]+, 421.3. 
 
4-(3-(3-(3,4-dichlorophenyl)ureido)benzamido) benzoic acid (24c). 
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 Compound synthesized as per method H, white solid with 61 mg in 77% yield; 1H NMR (400 MHz, 
CD3OD) δ ppm 10.54 (s, 1 H), 9.08 (d, J = 4.7 Hz, 2 H), 8.06-7.85 (m, 6 H), 7.69 (d, J = 7.8 Hz, 1 H), 
7.59 (d, J = 7.4 Hz, 1 H), 7.53 (d, J = 8.6 Hz, 1 H), 7.50-7.42 (m, 1 H), 7.36 (d, J = 9.0 Hz, 1 H); 
LCMS (ESI): found [M + Na]+, 445.3. 
 
 
 
ACKNOWLEDGMENTS 
We thank Qi Wang for her technical assistance related to clustering compounds and identifying 
representatives for screening. This work was supported by National Institute of Allergy and Infectious 
Diseases (NIAID) grant AI081803 to M.M. The study was also partly supported by NIAID grant 
AI056189 to R.V.A. 
 
AUTHOR CONTRIBUTIONS 
M.M. J.W.J., P.J.B., and R.A., conceived and designed the experiments. RT, J.J., and MM wrote the 
manuscript. A.R.M, R.C., and J.H, synthesized the compounds. C.F., C.A.B, J.S., M.E., performed in 
vitro and in vivo screening. M.Z., and J.H., performed the bioaccumulation assay. M.E, and C.A.B., 
prepared samples for the bioaccumulation assays. R.T., X.G., B.A.R., S.A.W., analyzed all the data. 
All authors edited the manuscript.  
 
Notes 
The authors declare no competing financial interest. 
 
ABBREVIATIONS USED 
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 FIGURE LEGENDS 
 
Figure 1. Overall workflow. (A) Identification of publicly available CPT-modulators: CPT orthologs in 
23 species were identified and used to find CPT homologs in ChEMBL’s target database. The 105 
compounds targeting these CPT homologs in the ChEMBL database were grouped into nine clusters 
based on their structure and five representatives were prioritized for screening after filtering for drug-
likeness, commercial availability and cost. (B) Synthesizing known mammalian CPT-modulators. Four 
known CPT inhibitor compounds were synthesized and used in in vitro screening. Two of these were 
found to be deleterious to the worms, and were used for docking studies. Based on the docking 
results 22 analogs were synthesized and used for in vitro screening. (C) in vitro screening was 
accomplished for a total of 33 compounds in adult stage of multiple parasitic nematode species, of 
those 10 were hits in both intestinal and filarial nematodes.  
 
Scheme 1.  Synthesis of known mammalian small molecule CPT inhibitors and analogs. (A) 
Synthesis of known compound 6a and its newly designed analogs. (B) Synthesis of known compound 
10a and its newly designed analogs. 
 
Scheme 2. Synthesis of known CPT inhibitors 17(a-b) as conformationally restricted sulfonamide 
analogs of 6a. 
 
Figure 2. In vitro screening in intestinal and filarial nematodes. (A) Compounds screened to identify 
their pan-phylum potential based on motility inhibition. For complete set of results and details on the 
molecular weight and tested concentrations see Table S4. Dose response assay data for 6a and its 
analogs 6c and 6d from in vitro screening of whipworm (B) and filarial nematode (C). This is a subset 
compiled from the full dataset to illustrate the most striking results.  
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 Figure 3.  (A) Molecular docking of inhibitors bound to T. muris CPT2 (orange) based on rat CPT2 
2FW3 (magenta). (B) Overlay of 6a (cyan), 10a (green) and 17a (yellow). Residues of CPT2 
homology model in T. muris are in orange and rat CPT2 is in magenta. Targeted differences in the 
CoA binding site of T. muris are shown as sticks. (i) Thr (rat), Val (Tm); (i) Phe (rat), Tyr (Tm); (iii) Lys 
(rat), Arg (Tm); (iv) Asn (rat), Thr (Tm). 
 
Figure 4. Rational design chemistry plan: (A) 6a and (B) 10a. 
 
Scheme 3. Synthesis of compounds 24(a-c) as novel urea analogs of known CPT inhibitor 10a. 
 
Figure 5. Perhexiline reduces fecal egg count but not total worm load. (A) Treatment with perhexiline 
significantly reduced fecal egg count in Syrian hamsters infected with the hookworm A. ceylanicum 
compared with untreated control animals. (B) The fecal egg count reduction was not accompanied by 
a reduction of worm load, which was not statistically significant between control and treated animals. 
(C) and (D) RNAseq based gene expression profile over developmental stages of A. ceylanicum 
shows increased expression of CPT1/2 in adult female compared to L4 female, L4 male and adult 
male.  
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Figure 1. Overall workflow. (A) Identification of publicly available CPT-modulators: CPT orthologs in 23 
species were identified and used to find CPT homologs in ChEMBL’s target database. The 105 compounds 
targeting these CPT homologs in the ChEMBL database were grouped into nine clusters based on their 
structure and five representatives were prioritized for screening after filtering for drug-likeness, commercial 
availability and cost. (B) Synthesizing known mammalian CPT-modulators. Four known CPT inhibitor 
compounds were synthesized and used in in vitro screening. Two of these were found to be deleterious to 
the worms, and were used for docking studies. Based on the docking results 22 analogs were synthesized 
and used for in vitro screening. (C) in vitro screening was accomplished for a total of 33 compounds in adult 
stage of multiple parasitic nematode species, of those 10 were hits in both intestinal and filarial nematodes. 
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Scheme 1.  Synthesis of known mammalian small molecule CPT inhibitors and analogs. (A) Synthesis of 
known compound 6a and its newly designed analogs. (B) Synthesis of known compound 10a and its newly 
designed analogs.  
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Scheme 2. Synthesis of known CPT inhibitors 17(a-b) as conformationally restricted sulfonamide analogs of 
6a.  
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Figure 2. In vitro screening in intestinal and filarial nematodes. (A) Compounds screened to identify their 
pan-phylum potential based on motility inhibition. For complete set of results and details on the molecular 
weight and tested concentrations see Table S4. Dose response assay data for 6a and its analogs 6c and 6d 
from in vitro screening of whipworm (B) and filarial nematode (C). This is a subset compiled from the full 
dataset to illustrate the most striking results.  
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Figure 3.  (A) Molecular docking of inhibitors bound to T. muris CPT2 (orange) based on rat CPT2 2FW3 
(magenta). (B) Overlay of 6a (cyan), 10a (green) and 17a (yellow). Residues of CPT2 homology model in T. 
muris are in orange and rat CPT2 is in magenta. Targeted differences in the CoA binding site of T. muris are 
shown as sticks. (i) Thr (rat), Val (Tm); (i) Phe (rat), Tyr (Tm); (iii) Lys (rat), Arg (Tm); (iv) Asn (rat), Thr 
(Tm).  
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Figure 4. Rational design chemistry plan: (A) 6a and (B) 10a.  
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Scheme 3. Synthesis of compounds 24(a-c) as novel urea analogs of known CPT inhibitor 10a.  
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Figure 5. Perhexiline reduces fecal egg count but not total worm load. (A) Treatment with perhexiline 
significantly reduced fecal egg count in Syrian hamsters infected with the hookworm A. ceylanicum 
compared with untreated control animals. (B) The fecal egg count reduction was not accompanied by a 
reduction of worm load, which was not statistically significant between control and treated animals. (C) and 
(D) RNAseq based gene expression profile over developmental stages of A. ceylanicum shows increased 
expression of CPT1/2 in adult female compared to L4 female, L4 male and adult male.  
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